0 ECCMID19: Vaccine-preventable diseases on the rise in Venezuela
Vaccine-preventable diseases – including measles and diphtheria – have surged in crisis-hit Venezuela, according to research presented at ECCMID.
Browsing: Clinical > Vaccines
0 ECCMID19: Immune response to Ebola 2 years post-infection could provide clues for vaccine development
Two years after Ebola infection, survivors exhibit specific memory T cell responses against ebolavirus, according to new research presented at ECCMID.
0 Phase III study of Novavax’s RSV vaccine fails primary objective: March’s industry headlines
Take a look at this month’s industry headlines including news on Sanofi’s Dengvaxia® vaccine from the USA and the Philippines, clinical trial results for RSV vaccines and HIV injectables and new acquisitions for Merck.
0 Developing a maternal vaccine against respiratory syncytial virus
Recently, many programs developing respiratory syncytial virus vaccines have sought to vaccinate pregnant women in an effort to enhance maternal immunity. Find out about the challenges and the latest developments.
0 Ethically possible and ethically required: The path towards equitable inclusion of pregnant women in vaccine development
Vaccination during pregnancy provides important benefits, so why are pregnant women excluded from clinical trials? Learn more about the path towards including this group in vaccine development for both routine and emergency vaccinations.
0 Mayaro virus: novel synthetic DNA vaccine provides immunity in preclinical trials
Researchers from the Wistar Institute have engineered a synthetic DNA vaccine able to provide potent immunity against the emerging Mayaro virus in mice models.
0 Micromotor formulation shows promise for oral vaccination
A biomimetic, micromotor vaccine formulation has shown promising results in immunizing against Staphylococcus aureus in mouse models.
0 Infographic: The pipeline for RSV vaccines
In this infographic we take a look at the RSV vaccines currently in the clinical pipeline and their target population from Phase I to Phase III.
0 New partnerships for antibiotic discovery and further cuts in the field: December’s industry headlines
Take a look at this month’s industry headlines including a new partnership for antibiotic development, approval for HIV drugs and authorization for a cytomegalovirus test.
0 Could an mRNA vaccine be protective against emerging tick-borne viruses?
An mRNA-based vaccine has been demonstrated to protect against Powassan virus in mice, in addition to also conferring protection against the more distantly related Langat virus.
